Ann Surg by Herndon, David N. et al.
Reversal of Growth Arrest with the Combined Administration of 
Oxandrolone and Propranolol in Severely Burned Children
David N. Herndon, MD1,3,6,*, Charles D. Voigt, MD1,6,*, Karel D. Capek, MD1,6, Paul Wurzer, 
MD1,6,7, Ashley Guillory, PhD1,6, Andrea Kline, BA1,6, Clark R. Andersen, MS1,6, Gordon L. 
Klein, MD1,4,6, Ronald G. Tompkins8, Oscar E. Suman, PhD1,6, Celeste C. Finnerty, 
PhD1,2,3,6, Walter Meyer, MD5,6, and Linda E. Sousse, PhD1,6,*
1Department of Surgery, University of Texas Medical Branch, Galveston, Texas 77555, USA
2Sealy Center for Molecular Medicine, University of Texas Medical Branch, Galveston, Texas 
77555, USA
3Institute for Translational Sciences, University of Texas Medical Branch, Galveston, Texas 77555, 
USA
4Department of Orthopedic Surgery and Rehabilitation, University of Texas Medical Branch, 
Galveston, Texas 77555, USA
5Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, 
Galveston, Texas 77555, USA
6Shriners Hospital for Children®—Galveston, Galveston, Texas 77550, USA
7Division of Plastic Aesthetic and Reconstructive Surgery, Department of Surgery, Medical 
University of Graz, 8010 Graz, Austria
8Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
Abstract
Background—The hypercatabolic response in severely burned pediatric patients is associated 
with increased production of catecholamines and corticosteroids, decreased formation of 
testosterone, and reduced strength alongside growth arrest for up to 2 years post injury. We have 
previously shown that, in the pediatric burned population, the administration of the testosterone 
analog oxandrolone improves lean body mass accretion and bone mineral content and that the 
administration of the β1, β2 adrenoreceptor antagonist propranolol decreases cardiac work and 
resting energy expenditure while increasing peripheral lean mass. Here, we determined whether 
the combined administration of oxandrolone and propranolol has added benefit.
Methods—In this prospective, randomized study of 612 burned children (52 ± 1% of total body 
surface area burned, ages 0.5–14 years [males]; ages 0.5–12 years [females]), we compared 
controls to the individual administration of these drugs, and the combined administration of 
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oxandrolone and propranolol at the same doses, for 1 year post burn. Data were recorded at 
discharge, 6 months, and 1 and 2 years post injury.
Results—Combined use of oxandrolone and propranolol shortened the period of growth arrest by 
84 days (p=0.0125 vs. control) and increased growth rate by 1.7 cm/y (p=0.0024 vs. control).
Conclusion—Combined administration of oxandrolone and propranolol attenuates burn-induced 
growth arrest in pediatric burn patients. This study is registered at clinicaltrials.gov: 
NCT00675714 and NCT00239668.
Growth Arrest and Growth Rate By Treatment Group




Control 280 ± 19 5.9 ± 0.2
Oxandrolone 217 ± 17 5.8 ± 0.3
Propranolol 242 ± 13 6.3 ± 0.2
Oxandrolone + Propranolol 196 ± 15* 7.6 ± 0.5*




The combined use of the testosterone analog oxandrolone and the β-adrenoreceptor antagonist 
propranolol shortened the period of growth arrest and increased the rate of growth compared to 
control and compared to the administration of oxandrolone and propranolol individually in 
pediatric burn subjects during growth spurt years.
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INTRODUCTION
Severe burn injuries induce a significant hypermetabolic state characterized by a severe loss 
of lean body mass, muscle wasting, and growth delays.1–3 Bone loss also begins quickly and 
is sustained following burn injuries in children, increasing the risks of post-burn fractures 
and reducing bone mass and growth velocity.4, 5 We have previously reported that the daily 
administration of the non-aromatizable androgen oxandrolone (Ox), an orally-active 
synthetic non-virilizing testosterone derivative, for 1 year post burn significantly reduces 
hypermetabolism and significantly increases bone mineral content, lean body mass, and 
strength in pediatric burned patients when assessed 1 year post burn.6
Propranolol (Prop) is a non-selective β-adrenoreceptor antagonist that mitigates the 
catecholamine response associated with burns. Significant reductions in the percent of 
predicted heart rate and percent of predicted resting energy expenditure, prevention of bone 
loss, and improvement of lean body mass accretion result when Prop is administered at a 
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dose to decrease heart rate by 15% for 1 year in pediatric burn patients.7 We have also 
shown that burned children receiving Prop have improved protein synthesis, muscle protein 
synthesis efficiency, and muscle protein net balance after treatment for 2 weeks compared to 
untreated burned children.8 Prop treatment attenuates the hyperdynamic, hypermetabolic, 
hypercatabolic, and osteopenic responses following severe burn injury in pediatric patients.7
The specific objectives of our study were to evaluate whether the combined administration 
of Ox and Prop attenuates growth arrest and improves the rate of growth, as measured in 
centimeters grown per year, compared to the administration of Ox or Prop alone. We 
hypothesized that the combined administration of Ox and Prop in burned pediatric subjects 
would have improved growth outcomes compared to untreated subjects or to subjects treated 
with Ox or Prop alone. Our study compared four groups of pediatric burn patients who were 
admitted to Shriners Hospital for Children®—Galveston from 1997 to 2015. Specifically, 
males between the ages of 0.5 and 14 years and females between the ages of 0.5 to 12 years 
were assessed. The upper limits of the age ranges were eliminates the variable onset of post-
pubescent growth delay.
MATERIALS AND METHODS
Subject Demographics and Injury Characteristics
A total of 6,361 patients were admitted to Shriners Hospital for Children®—Galveston 
between November 1997 and October 2015. Of the 6,361 patients, 1,039 consented to 
participate in research protocols after meeting the following inclusion criteria: (1) 0.5 to 18 
years of age and (2) ≥30% of the total body surface area (TBSA) burned. Six hundred twelve 
subjects of the 1,039 subjects were included in this prospective, intent-to-treat study. All 
were males between 0.5 or 14 years or females between 0.5 and 12 years. Subjects were 
prospectively assigned to one of four treatment groups using a randomization schedule 
generated with random allocation sequence software. Subjects received one of the following 
treatments during their acute stay and for 1 year post discharge: (a) control treatment (Ctrl; 
n=248), (b) Ox (BTG Pharmaceuticals, West Conshohocken, PA; 0.1 mg/kg every 12 hours 
for 1 year minimum; n=67), (c) Prop (Roxane Laboratories, Columbus, OH; 4.0 ± 0.2 
mg/kg/day for 1 year minimum, dose titrated to decrease heart rate by 15%; n=194), (d) 
combined administration of Ox and Prop [OxProp; n=103] (Figure 1). If bradycardia 
occurred, a single dose of propranolol was held and administration recommenced after 16 
hours with one half of the original dose. The dose was then escalated back to the original 
dose over the following 24 hours. Ctrl subjects were enrolled continuously from 1997 to 
2015, and Ctrl subjects outnumbered subjects in the Ox, Prop, and OxProp groups because 
of the balanced design of the randomization schedule for subjects in all studies at Shriners 
Hospital for Children®—Galveston (Figure 2). Subjects were enrolled in OxProp beginning 
in 2003, and breaks in OxProp enrollment were taken from 2005 to 2007 and from 2008 to 
2009 to study Ox and Prop subjects. Study drugs were started within 4 ± 0.5 days post 
admission. Subjects were blinded to their treatment group, and the appropriate dose of 
propranolol was determined by a physician blinded to the study treatments. Patients were 
excluded due to decision not to treat due to severity of injury, and/or anoxic brain injury. 
Patient age, sex, ethnicity, percent of TBSA burned, and percent of TBSA with third-degree 
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burns were recorded at the time of admission. Age-appropriate diagrams were used to 
determine burn size.9 All subjects received the standard of care for wound treatment and 
nutrition as described previously.10
This study was approved by the Institutional Review Board of the University of Texas 
Medical Branch (Galveston, TX). Informed written consent was obtained from the subject’s 
legal guardian before enrollment in the study. Written assent was also obtained from the 
subject if he/she was 7 years old or older. Subjects were assessed at discharge, 6 months, 1 
and 2 years post burn, and subjects who withdrew from the study were included in the data 
analysis until the time of withdrawal. All study staff, including study physicians, attended 
protocol initiation meetings at the outset of the study to review enrollment criteria and all 
study-related procedures. They met weekly thereafter to review progress of all subjects and 
ensure continued protocol adherence. Subject data entered into CRFs and the study database 
was subject to regular quality-control checks. This study is part of a larger clinical trial 
(clinicaltrials.gov: No. NCT00675714) evaluating outcomes following administration of 
several therapeutic agents in burns.
Growth Arrest and Growth Rate
Endpoints for growth, which were assessed using height and body weight measurements, 
were collected from each subject at admission, throughout their acute stay, at discharge, 6 
months post burn, and annually at all follow-up appointments. The duration of growth arrest 
was defined as the days from the date of burn to the date at which each subject was 
determined to have passed their admission height by at least 0.25 cm and where the height 
increase was persistent and progressive. This end date of growth arrest was collectively 
determined by the examination of growth data by three physicians who were blinded to drug 
cohort assignment. Growth rate was modeled using linear regression of the heights at the end 
date of growth arrest through subsequent follow-up visits males reached the age of 14 years 
and females reached the age of 12 years. The latter was determined clinically by using sex, 
age, and height-for-age percentiles; only data from males ages 2–14 years and females ages 
2–12 years was included in the growth rate analysis.11
Statistical Analysis
Differences among groups in days between burn and end of growth arrest were assessed by 
permutation t-tests. This approach was chosen due to heterogeneous skewness of 
distributions between the groups; the data from the Ctrl and Prop-treated groups were 
strongly right-skewed, while the Ox and OxProp groups showed little evidence of skewness. 
Hommel-adjusted p values compensated for multiple comparisons among groups.12 Growth 
slope (cm/y) was modeled by multiple linear regression with relation to age at burn, percent 
of TBSA burned, and treatment group. Differences among treatments and times were 
assessed by Tukey-adjusted contrasts. All statistical testing assumed a 95% level of 
confidence (p<0.05), and all analyses were performed using R statistical software.13
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The demographic data from our burned patient population randomized into the Ctrl, Ox, 
Prop, and OxProp groups are presented in Table 1. Ctrl subjects (n=248) did not receive 
study drug. Subjects who were randomized into the Ox group (n=67) received 0.1 mg/kg Ox 
every 12 hours for 1 year, while Prop subjects (n=194) received 4.0 ± 0.2 mg/kg/day Prop 
for 1 year, and subjects randomized to OxProp (n=103) received both 0.1 mg/kg Ox every 12 
hours for 1 year and 4.0 ± 0.2 mg/kg/day Prop for 1 year. There were no significant 
differences among the four groups in age (p=0.47), sex (p=0.20), ethnicity (p=0.28), percent 
of TBSA burned (p=0.47), percent of TBSA with third-degree burns (p=0.69), mortality 
(p=0.31), length of stay (p=0.48), body mass index (p=0.51), or weight (p=0.23). The range 
of admission times in all groups is shown in Figure 2.
There was a bimodal temporal pattern from burn to time of admission in our subjects. Table 
2 summarizes the burn to admission times of the immediate (burn to admission: <7.5 days) 
and delayed (burn to admission: >7.5 days) subjects. Both groups were included in our study 
because the primary outcome, which is the number of days of growth arrest between the Ctrl 
and OxProp groups, was significant with or without the inclusion of delayed admission 
subjects (all subjects: p=0.0125, Table 3).
Duration of Growth Arrest & Growth Rate
Table 3 shows means and p values for Ctrl (median; 221 days of growth arrest), Ox (median, 
239 days), Prop (median, 206 days), and OxProp (median, 180 days; Figure 3). The Ctrl 
group averaged 84 more days of growth arrest than the OxProp group (p=0.0125).
The subjects treated with OxProp grew 1.7 cm/y more than Ctrl-treated subjects (median, 
6.0 cm/y; p=0.0024), with an adjusted 95% CI spanning 0.4 to 2.6 (Table 3, Figure 4). 
OxProp (median, 6.9 cm/y) averaged 1.8 cm/y greater growth than Ox (median, 5.6 cm/y; 
p=0.0145), with an adjusted 95% CI spanning 0.2 to 3.0. OxProp also averaged 1.3 cm/y 
greater growth than Prop (median, 6.4 cm/y; p=0.0145), with an adjusted CI spanning 0.2 to 
2.4.
There was no evidence of a significant effect due to sex (p=0.40 for days of growth arrest, 
p=0.09 for growth rate). Age had significant effects on time to growth arrest and on growth 
rate and thus was included as a covariate in our statistical models. The year of burn was a 
significant covariate; however, the increases in growth rate with OxProp treatment remained 
significantly different compared to the Ctrl group (p=0.0337) and compared to the Prop 
group (p=0.0178). Also, growth arrest was significantly different between the Ox and Ctrl 
groups (p=0.0009) and the Prop and Ox groups (p=0.0062).
Safety Profile
Subjects were closely monitored for adverse events during their acute stay and at every 
follow-up visit post-discharge; all adverse events were reviewed by the Data Safety 
Monitoring Board. Clitoral hood edema developed in three female subjects randomized to 
the Ox group, and the edema resolved in 3 months.
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The trauma from burn injury results in adaptive responses by the body including the 
systemic inflammatory and stress hormone responses. The consequences of these sequelae 
include muscle wasting and bone loss in conjunction with stunted growth. Our present study 
showed that the combined administration of Ox and Prop significantly improved growth 
arrest by an average of 84 days compared to the Ctrl treatment. Also, we showed that 
OxProp significantly increased growth rate compared to the Ctrl treatment and compared to 
Ox or Prop alone. In this analysis, we included males between ages 0.5 to 14 years and 
females between ages 0.5 to 12 years at the time of burn. This age range was used to 
examine the pediatric growth period. During these age spans, unburned males grow at an 
average rate 6.5 cm/y and unburned females grow at an average rate of 6.7 cm/y.14, 15 Height 
velocity reaches a plateau at 14 years for males and 12 years for females in the non-burned 
population.11
In our previous studies, Ox (0.1 mg/kg every 12 hours) administered for 1 year post burn to 
pediatric burned subjects increased muscle mass at 6 months post burn and improved bone 
mineral content and density at 1 year post burn.6 The reasons for the delay in the effects of 
Ox on the bone and muscle are unknown. Oxidative stress increases after burn, and 
scavengers of reactive oxygen and nitrogen species are significantly depleted in burned 
patients.16 We postulate that the elevated inflammatory cascade and additional oxidative 
stress associated with burns may interfere with bone strength and muscle integrity and may 
delay the effects of Ox.
A wide array of inflammatory cytokines are consistently elevated after burn injury, including 
IL-1β, IL-6, and TNF-α.17 We have previously shown that Prop decreases inflammatory 
cytokines such as TNF-α and IL-1β in pediatric burn subjects during their acute 
hospitalization.18 Also, our studies showed that combined administration of Prop with 
recombinant human growth hormone in 15 pediatric burned subjects significantly decreased 
serum C-reactive protein, cortisone, IL-6, and IL-8 as well as significantly increased serum 
insulin-like growth factor-I, insulin-like growth factor binding protein-3, and growth 
hormone compared to control treatment.19 TNF-α and IL-1β have been shown to decrease 
osteoclast formation and bone resorption in murine models, and TNF-α, IL-1β, and IL-6 
increase bone loss in mice.20, 21 The anti-inflammatory properties of Prop have been well-
documented; its use has been associated with decreased edema in mesenchymal stromal 
cells with traumatic brain injury22 as well as decreased cardiac inflammation and oxidative 
stress markers such as glutathione and isoprostanes.23 Prop attenuates inflammatory cell 
infiltration, expression of the cytokines TNF-α and IL-8,24 and airway inflammation25 in a 
rat model of cigarette smoke exposure. The combined administration of Ox and Prop may 
stimulate protein synthesis and anabolism owing to Ox and decrease the inflammatory 
cascade owing to Prop, resulting in an additive effect that increases growth of pediatric burn 
patients.
Burn injury induces production of epinephrine26, 27 and glucocorticoids,28 both of which 
have anti-chondrogenic effects,29 and these increases last up to 3 years post burn. High 
concentrations of glucocorticoids are associated with shorter height in children,30 shorter 
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femur growth and reduced bone density in young rabbits,31, 32 and reduced size of the 
growth plates in the tibiae of rats.33 Exposure to 30 nM of testosterone improves 
chondrogenesis in human intervertebral disc cells by increasing the expression of aggrecan, 
collagen type I, and type II collagen in particular.34 Chondrogenesis and myogenesis are 
induced in the larynx of South African clawed frogs by testosterone, which stimulates 
satellite cell division, further increasing muscle mass.35 Additionally, Takarada and 
colleagues showed that epinephrine inhibits the gene transactivation necessary for 
chondrogenic differentiation. Furthermore, Prop prevented this response to epinephrine in 
ATDC5 cells and primary cultured mouse costal chondrocytes.29 The administration of Prop 
significantly increased the expression of collagen I and X mRNA in fractured murine femurs 
in similar experiments.29 Since testosterone has chondrogenic properties and Ox is a 
testosterone analog, we speculate that Ox and Prop both have chondrogenic properties that 
may synergistically stimulate linear growth in pediatric burn patients.
Ox may cause perturbation of the immune response, which could potentially be attenuated 
by co-administering Ox with Prop. The use of Ox has been associated with the impairment 
of host defense by exacerbating systemic inflammatory response syndrome. In contrast, the 
influx of inflammatory neutrophils and monocytes associated with burn has been 
significantly mitigated in burned models treated with Prop,36, 37 and the addition of Prop to 
Ox may decrease the incidence of immunosuppression and improve host antibacterial 
defenses.
Limitations of our study include (1) the temporal differences between burn and admission 
among the immediate and delayed groups, and (2) the year of admission between all four 
groups. We have previously obtained substantial evidence of the beneficial effects of Ox and 
Prop alone in short-term studies38–44 and then began enrolling subjects in respective long-
term clinical trials beginning in 1997 (Figure 2). Ctrl subjects were enrolled continuously 
from 1997 to 2015 to correct for the evolving standard of care at our burn unit. Once we 
determined the efficacy and clinical outcomes of Ox and Prop individually,8, 45, 46 subjects 
were enrolled in OxProp beginning in 2003. Breaks in OxProp enrollment were taken from 
2005 to 2007 and 2008 to 2009 to confirm that the effects of Ox and Prop individually were 
maintained, regardless of the year of admission. There is no evidence of any differences 
among the groups in regards to age, percent of TBSA burned, percent of TBSA with third-
degree burns, sex, race, length of stay, or mortality (Table 1), and the clinical care from 1997 
to 2015 has been consistently guided by one attending Chief-of-Staff/Surgeon to ensure 
continuity of care. The differences among groups in time between burn and admission do not 
appear to underlie the observed effects since there is no significant difference in growth 
arrest between the Ctrl and OxProp groups regardless of admission time from burn.
Within 6 weeks of severe burn injury, lumbar spine bone density is reduced by 7% from 
admission bone mass with no improvement seen during a 2-year follow-up.5, 47 There is also 
a 3% loss of total body bone mineral content, which does appear to recover between 18 to 24 
months post burn.47 With no apparent improvement in bone mass, severely burned children 
are at risk for reduced peak bone mass and stunted growth. Our findings show that the 
combined use of Ox and Prop improve growth arrest and growth rate. The use of both 
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therapies together in pediatric burn patients should be strongly considered in the clinical 
setting.
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Flow Diagram. Out of 6,361 acute pediatric admissions to Shriners Hospitals for 
Children®—Galveston between 1997 and 2015, 612 patients were included in our study. 
Inclusion criteria were based on age (0.5–12 years for male subjects, 0.5–14 years for female 
subjects at the time of the admission) and burn size (≥30% total body surface area burned).
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Years of enrollment for each group.
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Difference in duration of growth arrest among groups. Data are shown as mean ± standard 
error. *p=0.0125 vs. Ctrl.
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Difference in growth slope among groups. Data are shown as mean ± standard error. 
*p=0.0024 vs. Ctrl; †p=0.0145 vs. Ox;‡ p=0.0145 vs. Prop.
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Table 3
Duration of Growth Arrest & Growth Rate




Ctrl 280 ± 19 5.9 ± 0.2
Ox 217 ± 17 5.8 ± 0.3
Prop 242 ± 13 6.3 ± 0.2
OxProp 196 ± 15* 7.6 ± 0.5§†‡
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